Trattamento della anemia sideropenica in patologie croniche in età pediatrica: il ferrocarbossimaltosio tra le nuove formulazioni di ferro ad uso endovenoso

Treatment of sideropenic anemia in chronic disease in children: ferrocarboxymaltose among the newformulations of iron for intravenous use

Teresa Capriati1, Donatella Comparcola2, Maria Rita Sartorelli2

1UOS Nutrizione Artificiale, Ospedale Pediatrico Bambino Gesù,Roma
2UOS Malattie Epatometaboliche, Ospedale Pediatrico Bambino Gesù,Roma

Iron deficiency anemia (IDA) continues to be very commonworldwide. Intravenous (IV) iron is an infrequently usedtherapeutic option in children with IDA despite numerousstudies in adults and several small but notable pediatricstudies showing efficacy and safety. Presently, theavailability of newer IV iron products allows for replacementof the total iron deficit at a single setting. These productsappear safer compared to the high molecular weight irondextrans of the past. Herein, we review the medical literatureabout Ferric carboxymaltose (ferinject, Injectafer) that is anintravenous iron preparation for the treatment of irondeficiency in various populations with IDA like patients withchronic disease such us heart failure chronic, kidneydisease, inflammatory bowel disease.

Scarica il PDF